StockData
Immix Biopharma, Inc. logo

Immix Biopharma, Inc. (IMMX) stock

IMMXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$7.20−0.28 (-3.74%)

Close on Nov 17, 2026Market cap $515.08MP/E –Yield –

Immix Biopharma r&d expenses

Research and development expenses are spending on new products and technology.

Immix Biopharma's R&D Expenses for the twelve months ending Jun 30, 2026 was $21.62M, up 83.8% year over year. For fiscal 2025 it was $16.26M, up 44.0% from the year before. The highest annual figure on record is $16.26M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$16.26M+44.0%
FY2024Dec 31, 2024$11.29M+29.3%
FY2023Dec 31, 2023$8.74M+108.2%
FY2022Dec 31, 2022$4.20M+3216.1%
FY2021Dec 31, 2021$126.53K-49.0%
FY2020Dec 31, 2020$248.15K–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$5.33M+34.3%
Q1 FY2026Mar 31, 2026$5.98M+202.8%
Q4 FY2025Dec 31, 2025$5.73M+316.7%
Q3 FY2025Sep 30, 2025$4.58M+3.1%
Q2 FY2025Jun 30, 2025$3.97M+78.6%
Q1 FY2025Mar 31, 2025$1.98M-39.2%
Q4 FY2024Dec 31, 2024$1.37M-55.7%
Q3 FY2024Sep 30, 2024$4.45M+111.1%
Q2 FY2024Jun 30, 2024$2.22M+0.7%
Q1 FY2024Mar 31, 2024$3.25M+146.3%
Q4 FY2023Dec 31, 2023$3.10M+37.0%
Q3 FY2023Sep 30, 2023$2.11M+202.6%
Q2 FY2023Jun 30, 2023$2.21M+263.5%
Q1 FY2023Mar 31, 2023$1.32M+109.5%
Q4 FY2022Dec 31, 2022$2.26M+24397.2%
Q3 FY2022Sep 30, 2022$695.94K+2244.0%
Q2 FY2022Jun 30, 2022$607.75K+868.4%
Q1 FY2022Mar 31, 2022$629.53K+2434.3%
Q4 FY2021Dec 31, 2021$9.24K–
Q3 FY2021Sep 30, 2021$29.69K–
Q2 FY2021Jun 30, 2021$62.76K–
Q1 FY2021Mar 31, 2021$24.84K–

More Immix Biopharma figures

See a number that looks wrong?